Stock Ratings / Health Care / RZLT / forecast

AVTX (34) CAPR (49) ALT (38) ASMB (31) ⌘ Pro Terminal →

Rezolute Inc. (NV) (RZLT) 12-Month Stock Forecast & Price Target Cone

$4.12 -2.37% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $4.09

Rezolute Inc. (NV) (RZLT) carries a Roarable Rating of E (Strong Sell) with 33/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (33/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $398.5M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $4.09 (-0.62%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (33/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.9% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-11.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for RZLT)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (33/100 Composite)

🔍 WHY RZLT SCORES 33/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (30% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (24% of score)

FRED Regime × Technicals: 29% of 52W Range • RSI-14 at 45.9 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$4.87-26.5% Next Q

Q2 (-2Q)

Grade E$3.58+7.8% Next Q

Q3 (-1Q)

Grade E$3.86+6.7% Next Q

Current

Grade E$4.12-8.9% Hist 90D α

Trajectory: D (41) → E (33)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a RZLT Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While RZLT currently carries a cautious 33/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.25) and Max Pain ($4.33) forces dealer call-delta covering toward $12.03.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $RZLT• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “RZLT Beats Next Quarter EPS Consensus (Dec 28, 2026) & Holds Above 200D SMA”

YES 33%NO 67%Trade / Inspect Odds →

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your RZLT Position Size: $10,000

Shares at $4.12: 2427.2 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $2.85

$6,917

$-3,083 (-30.8%)

12M Consensus BaseTarget $3.66

$8,883

$-1,117 (-11.2%)

12M Bull Case BreakoutTarget $12.03

$29,199

+$19,199 (+192.0%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 9

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$4	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$11	69%	B
JP MorganUS Large-Cap Research	SELL	$3	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring RZLT)

✓Walkthrough of RZLT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

RZLT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +28.75%📐 HORIZONTAL RANGE

2026-10-30O $4.05H $4.16L $3.88C $4.12VOL 779.0K

RES: $5.94SUP: $3.26SMA50: $4.25SMA200: $3.89

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

RZLT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 RZLT Butterfly Map → + Track RZLT →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on RZLT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for RZLT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for RZLT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (RZLT)

Health Care Rank #866 of 1016 ⚔️ AVTX vs RZLT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (RZLT vs. AVTX, CAPR, ALT, ASMB)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Rezolute Inc. (NV) (RZLT) ranks #866 by composite RQD confidence (33/100, grade E) and #482 by equity capitalization ($398.5M). Within this direct 5-issuer industry benchmark cohort, RZLT leads on earnings valuation at N/A trailing P/E, while ASMB leads on capital efficiency and profitability with -6.5% ROIC and — gross margin. CAPR currently holds the highest overall quantitative score in the immediate peer group at 49/100 (D) compared with RZLT at 33/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
RZLT ACTIVE Rezolute Inc. (NV)	E	33/100	—	—	-35.0%	-2.37%	$398.5M	Benchmark Subject
AVTX Avalo Therapeutics Inc.	E	34/100	—	—	-35.0%	+4.49%	$399.0M	/avtx-vs-rzlt →
CAPR Capricor Therapeutics Inc.	D	49/100	—	—	-35.0%	+6.42%	$385.5M	/capr-vs-rzlt →
ALT Altimmune Inc.	D-	38/100	—	—	-34.7%	+1.91%	$416.3M	/alt-vs-rzlt →
ASMB Assembly Biosciences Inc.	E	31/100	—	—	-6.5%	+1.41%	$424.7M	/asmb-vs-rzlt →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-06-30 • CIK 0001509261

In its most recent audited fiscal period (FY2025, filed 2025-06-30), Rezolute Inc. (NV) (RZLT) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$74.4M, operating cash flow of -$69.1M, and free cash flow of -$69.1M (-20.4% YoY). On the balance sheet, RZLT closed FY2025 with $138.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-06-30	$0	-$74.4M	-$69.1M	-$69.1M	$138.6M	—
FY2024 (FY)	2024-06-30	$0	-$68.5M	-$57.4M	-$57.4M	$112.0M	—
FY2023 (FY)	2023-06-30	$0	-$51.8M	-$44.5M	-$44.5M	—	—

3. RZLT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is RZLT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Rezolute Inc. (NV) (NASDAQ: RZLT) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $4.12 (-2.37% 1D, market cap $398.5M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, RZLT ranks #866 in composite RQD confidence.

How does RZLT compare to AVTX and CAPR in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RZLT carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, AVTX (Avalo Therapeutics Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $399.0M) and CAPR (Capricor Therapeutics Inc.) posts a D grade (49/100 RQD, P/E N/A, ROIC -35.0%, cap $385.5M). Among the 5-stock peer group, RZLT leads on earnings multiple (N/A) while ASMB leads on capital efficiency (-6.5% ROIC).

What are the biggest fundamental strengths and SEC risk factors for RZLT?

Per RZLT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001509261), Rezolute Inc. (NV) generated $0 in revenue, -$74.4M in net income, and -$69.1M in free cash flow against $138.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is RZLT trading relative to its 50-day, 200-day, and 52-week technical levels?

RZLT last traded at $4.12 (-2.37% on volume of 756,271 shares), positioning the stock -3.06% below its 50-day simple moving average ($4.25) and +5.91% above its 200-day simple moving average ($3.89). Across its 52-week range of $1.07 to $11.46, RZLT sits at the 29.4% percentile with a 14-day RSI of 45.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.60 to $4.64).

RZLT Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is RZLT's 12-month stock price target?

Rezolute Inc. (NV) (RZLT) carries a 12-month consensus base price target of $3.66 (-11.2% from $4.12), with a bull-case target of $12.03 and a bear-case floor of $2.85.

Is RZLT stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates RZLT E (Strong Sell — SELL) with an RQD Confidence score of 33/100.

Direct Sub-Reports: RZLT RQD Cockpit RZLT 12M Forecast RZLT Earnings & Move RZLT Dividends & DRIP RZLT Insiders & 13F RZLT Whale Options RZLT Profit Sankey RZLT News & Why